BACKGROUND: Cyclin D1-positive B cells are occasionally found in the mantle zones of reactive lymphoid follicles, a condition that has been called "in situ mantle cell lymphoma". The clinical significance of this lesion remains uncertain. DESIGN AND METHODS: The clinical and pathological characteristics, including SOX11 expression, of 23 cases initially diagnosed as in situ mantle cell lymphoma were studied. RESULTS: Seventeen of the 23 cases fulfilled the criteria for in situ mantle cell lymphoma. In most cases, the lesions were incidental findings in reactive lymph nodes. The t(11;14) was detected in all eight cases examined. SOX11 was positive in seven of 16 cases (44%). Five cases were associated with other small B-cell lymphomas. In two cases, both SOX11-positive, the in situ mantle cell lymphoma lesions were discovered after the diagnosis of overt lymphoma; one 4 years earlier, and one 3 years later. Twelve of the remaining 15 patients had a follow-up of at least 1 year (median 2 years; range, 1-19.5), of whom 11 showed no evidence of progression, including seven who were not treated. Only one of 12 patients with an in situ mantle cell lymphoma lesion and no diagnosis of mantle cell lymphoma at the time developed an overt lymphoma, 4 years later; this case was also SOX11-positive. The six remaining cases were diagnosed as mantle cell lymphoma with a mantle zone pattern. Five were SOX11-positive and four of them were associated with lymphoma without a mantle zone pattern. CONCLUSIONS: In situ mantle cell lymphoma lesions are usually an incidental finding with a very indolent behavior. These cases must be distinguished from mantle cell lymphoma with a mantle zone pattern and overt mantle cell lymphoma because they may not require therapeutic intervention.
BACKGROUND:Cyclin D1-positive B cells are occasionally found in the mantle zones of reactive lymphoid follicles, a condition that has been called "in situ mantle cell lymphoma". The clinical significance of this lesion remains uncertain. DESIGN AND METHODS: The clinical and pathological characteristics, including SOX11 expression, of 23 cases initially diagnosed as in situ mantle cell lymphoma were studied. RESULTS: Seventeen of the 23 cases fulfilled the criteria for in situ mantle cell lymphoma. In most cases, the lesions were incidental findings in reactive lymph nodes. The t(11;14) was detected in all eight cases examined. SOX11 was positive in seven of 16 cases (44%). Five cases were associated with other small B-cell lymphomas. In two cases, both SOX11-positive, the in situ mantle cell lymphoma lesions were discovered after the diagnosis of overt lymphoma; one 4 years earlier, and one 3 years later. Twelve of the remaining 15 patients had a follow-up of at least 1 year (median 2 years; range, 1-19.5), of whom 11 showed no evidence of progression, including seven who were not treated. Only one of 12 patients with an in situ mantle cell lymphoma lesion and no diagnosis of mantle cell lymphoma at the time developed an overt lymphoma, 4 years later; this case was also SOX11-positive. The six remaining cases were diagnosed as mantle cell lymphoma with a mantle zone pattern. Five were SOX11-positive and four of them were associated with lymphoma without a mantle zone pattern. CONCLUSIONS: In situ mantle cell lymphoma lesions are usually an incidental finding with a very indolent behavior. These cases must be distinguished from mantle cell lymphoma with a mantle zone pattern and overt mantle cell lymphoma because they may not require therapeutic intervention.
Authors: Armin G Jegalian; Franziska C Eberle; Svetlana D Pack; Mariya Mirvis; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe Journal: Blood Date: 2011-07-18 Impact factor: 22.113
Authors: Michele R Roullet; Daniel Martinez; Lisa Ma; Melissa Halpern Fowler; Ellen D McPhail; Alexander Judkins; Daniel A Arber; Adam Bagg Journal: Am J Clin Pathol Date: 2010-04 Impact factor: 2.493
Authors: Peter Martin; Amy Chadburn; Paul Christos; Karen Weil; Richard R Furman; Jia Ruan; Rebecca Elstrom; Ruben Niesvizky; Scott Ely; Maurizio Diliberto; Ari Melnick; Daniel M Knowles; Selina Chen-Kiang; Morton Coleman; John P Leonard Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544
Authors: P-Y Kuo; V V Leshchenko; M J Fazzari; D Perumal; T Gellen; T He; J Iqbal; S Baumgartner-Wennerholm; L Nygren; F Zhang; W Zhang; K S Suh; A Goy; D T Yang; W-C Chan; B S Kahl; A K Verma; R D Gascoyne; E Kimby; B Sander; B H Ye; A M Melnick; S Parekh Journal: Oncogene Date: 2014-03-31 Impact factor: 9.867
Authors: C Royo; A Navarro; G Clot; I Salaverria; E Giné; P Jares; D Colomer; A Wiestner; W H Wilson; M C Vegliante; V Fernandez; E M Hartmann; N Trim; W N Erber; S H Swerdlow; W Klapper; M J S Dyer; M Vargas-Pabón; G Ott; A Rosenwald; R Siebert; A López-Guillermo; E Campo; S Beà Journal: Leukemia Date: 2012-03-19 Impact factor: 11.528
Authors: Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo Journal: Virchows Arch Date: 2015-08-23 Impact factor: 4.064
Authors: Itziar Salaverria; Cristina Royo; Alejandra Carvajal-Cuenca; Guillem Clot; Alba Navarro; Alejandra Valera; Joo Y Song; Renata Woroniecka; Grzegorz Rymkiewicz; Wolfram Klapper; Elena M Hartmann; Pierre Sujobert; Iwona Wlodarska; Judith A Ferry; Philippe Gaulard; German Ott; Andreas Rosenwald; Armando Lopez-Guillermo; Leticia Quintanilla-Martinez; Nancy L Harris; Elaine S Jaffe; Reiner Siebert; Elias Campo; Sílvia Beà Journal: Blood Date: 2012-12-18 Impact factor: 22.113